Development
Cytokinetics, Incorporated
CYTK
$35.14
-$1.02-2.82%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 0.35% | 9.06% | -549.03% | -46.78% | -349.39% |
| Total Depreciation and Amortization | 282.09% | 31.68% | 31.84% | 37.81% | 125.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.72% | -33.79% | 33.96% | 26.57% | 8.14% |
| Change in Net Operating Assets | 166.50% | -87.38% | 74.30% | -147.35% | 149.48% |
| Cash from Operations | 24.60% | -14.48% | -34.63% | -356.10% | -119.48% |
| Capital Expenditure | 97.60% | 96.53% | 16.34% | 57.32% | 81.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -350.61% | 125.61% | 25.29% | 361.93% | -50.14% |
| Cash from Investing | -378.34% | 124.98% | 25.83% | 357.47% | -38.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -111.43% | 99.85% | 20.60% | 99.57% | -- |
| Issuance of Common Stock | 4,597.67% | -28.30% | 54.41% | -12.96% | -84.98% |
| Repurchase of Common Stock | -- | -- | -- | -9.53% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Financing | 464.83% | -86.06% | 60.28% | -107.65% | 53.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.14% | 146.32% | -56.95% | 1,207.47% | -276.69% |